Vivos Therapeutics (VVOS) Depreciation & Amortization (CF) (2020 - 2026)
Vivos Therapeutics (VVOS) reported Depreciation & Amortization (CF) of $454000.0 for Q1 2026, up 156.5% year-over-year from $177000.0 in Q1 2025, and up 2.71% on a QoQ basis from $442000.0 in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $454000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 156.5% year-over-year to $454000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 159.15% YoY) and the FY2025 annual result came in at $1.3 million, up 125.3% from the prior year.
- Depreciation & Amortization (CF) grew to $454000.0 in Q1 2026 per VVOS's latest filing, from $442000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $454000.0 in Q1 2026 and bottomed at $41000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $169000.0 (2022), against an average of $213764.7.
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) tumbled 76.84%; it then soared 326.83% in 2023.
- Tracing VVOS's Depreciation & Amortization (CF) over 5 years: stood at $169000.0 in 2022, then declined by 11.83% to $149000.0 in 2023, then decreased by 3.36% to $144000.0 in 2024, then soared by 206.94% to $442000.0 in 2025, then climbed by 2.71% to $454000.0 in 2026.
- Per Business Quant, the three latest VVOS Depreciation & Amortization (CF) figures stand at $454000.0 (Q1 2026), $442000.0 (Q4 2025), and $384000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 381.00 Mn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 120.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 749.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 351.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 40.90 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 67.10 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 78.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 123.40 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | 454,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 454,000.00 |
| Mar 31, 2026 | 454,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Dec 31, 2025 | 442,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Sep 30, 2025 | 384,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Jun 30, 2025 | 306,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Dec 31, 2024 | 144,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Sep 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Mar 31, 2024 | 146,000.00 |
| Dec 31, 2023 | 149,000.00 |
| Dec 31, 2023 | 149,000.00 |
| Sep 30, 2023 | 149,000.00 |
| Sep 30, 2023 | 149,000.00 |
| Jun 30, 2023 | 148,000.00 |
| Jun 30, 2023 | 148,000.00 |
| Mar 31, 2023 | 175,000.00 |
| Mar 31, 2023 | 175,000.00 |
| Dec 31, 2022 | 169,000.00 |
| Dec 31, 2022 | 169,000.00 |
| Sep 30, 2022 | 176,000.00 |
| Sep 30, 2022 | 176,000.00 |
| Jun 30, 2022 | 283,000.00 |
| Jun 30, 2022 | 283,000.00 |
| Mar 31, 2022 | 41,000.00 |
| Mar 31, 2022 | 41,000.00 |
| Dec 31, 2021 | 168,000.00 |
| Dec 31, 2021 | 168,000.00 |
| Sep 30, 2021 | 192,504.00 |
| Sep 30, 2021 | 192,504.00 |
| Jun 30, 2021 | 194,769.00 |
| Jun 30, 2021 | 194,769.00 |
| Mar 31, 2021 | 177,000.00 |
| Mar 31, 2021 | 177,000.00 |
| Dec 31, 2020 | 177,460.00 |
| Dec 31, 2020 | 177,460.00 |
| Sep 30, 2020 | 178,933.00 |
| Sep 30, 2020 | 178,933.00 |
| Jun 30, 2020 | 180,639.00 |
| Jun 30, 2020 | 180,639.00 |
| Mar 31, 2020 | 180,968.00 |
| Mar 31, 2020 | 180,968.00 |